PHIO
Phio Pharmaceuticals Corp.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 5 Phio Pharmaceuticals reported its 2025 financial results, highlighti…
- Jun 26 ▲ 1 insider buy $9.9K at $0.9900
- Aug 18 to Aug 19 ▲ 2 days of insider buys: $27.7K by 2 insiders, avg $1.11
- Aug 31 ▲ Short interest falls 30.7% to 221.5K
- Sep 15 to Sep 29 ▲ 5 days of insider buys: $31.4K by 3 insiders, avg $1.03
- Sep 15 ▲ Short interest falls 32.3% to 149.9K
- Sep 30 ▲ Short interest falls 40.3% to 89.5K
- Oct 15 ▼ Short interest jumps 52.5% to 136.4K
- Oct 30 ▲ Short interest falls 36.7% to 86.3K
- Nov 9 to Nov 11 ▲ 3 days of insider buys: $45.8K by 3 insiders, avg $0.8274
- Nov 12 New insider trade: subscribers see the details Unlock
- Nov 13 New insider trade: subscribers see the details Unlock
Signal stack
Where each data set points today.
- InsidersMIXED
4 insiders bought $114.7K. No open-market sales. Excludes 2 subscriber-only trades.
- InstitutionsMIXED
Q3 2026: 4 added (0 new), 3 trimmed or exited.
- AnalystsBULLISH
6 of 7 rate it Buy or better.
- Short sellersCOVERING
Short interest −36.7% to 86.3K shares. 1.5 days to cover, ≈0.7% of shares.
- TrendDOWNTREND
19% below its 50-day average. New closing low $0.7520 on Nov 16.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| VANGUARD FIDUCIARY TRUST CO | ADD | $78.4K |
| JANE STREET GROUP, LLC | TRIM | $63.3K |
| HRT FINANCIAL LP | ADD | $22.0K |
| UBS Group AG | TRIM | $3.2K |
| BARCLAYS PLC | NEAR_EXIT | $2.00 |
| HRT FINANCIAL LP | TRIM | $13.0K |
| CITIGROUP INC | DOUBLED | $11.9K |
| UBS Group AG | NEAR_EXIT | $5.5K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
7 analysts| Date | Firm | Rating |
|---|---|---|
| Aug 26, 2026 | HC Wainwright & Co. REITERATE | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
| 🔒 Fresh data, subscribers only Nov 13, 2026 | BUY | |
| 🔒 Fresh data, subscribers only Nov 12, 2026 | BUY | |
Deming David H Director Nov 11, 2026 | BUY | $4.4K |
Deming David H Director Nov 10, 2026 | BUY | $5.7K |
Bitterman Robert J Chairman, Pres. & CEO Nov 9, 2026 | BUY | $20.5K |
Plott Ronald Todd Director Nov 9, 2026 | BUY | $15.2K |
Plott Ronald Todd Director Sep 29, 2026 | BUY | $5.2K |
Bitterman Robert J Chairman, Pres. & CEO Sep 28, 2026 | AWARD | 400,000 sh |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
7 filings · 1 bullish · 1 bearish · 1 mixed · 4 neutral- BEARISH 8-KNov 5, 2026
Phio Pharmaceuticals reported Q3 2026 results with a net loss of $4.2M, wider than the $2.4M loss…
The FDA response on the Phase 2b study design, expected by end of November 2026, is the next major catalyst. Cash runway appears tight given the $10.6M balance and rising R&D spend; watch for…
- NEUTRAL 8-KOct 13, 2026
Phio Pharmaceuticals announced the successful completion of its first commercial-scale cGMP batch…
Monitor for initiation of the Phase 2b trial in Q1 2027 and any subsequent data readouts. No near-term catalyst from this manufacturing milestone alone.
- BULLISH 8-KSep 14, 2026
Phio Pharmaceuticals announced a key development milestone for its lead siRNA candidate PH-762…
This FDA submission is a modest positive catalyst for a pre-revenue micro-cap, but the stock's reaction will depend on the market's perception of the probability of FDA acceptance and the Phase 2b…
- NEUTRAL DEFA14AAug 14, 2026
Phio Pharmaceuticals Corp. filed a DEFA14A (additional definitive proxy soliciting materials) for…
This is a routine proxy notice with no material financial or operational news. The proposed 1,500,000 share increase to the equity plan is modest for a $13M market cap company and is standard…
All PHIO filing & press-release reports (7)
- 8-K reportNov 5, 2026
- 8-K reportOct 13, 2026
- 8-K reportSep 14, 2026
- DEFA14A reportAug 14, 2026
- 8-K reportApr 8, 2026
- 424B5 reportApr 8, 2026
- 8-K reportMar 5, 2026